These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Defective T-cell receptor-induced apoptosis of T cells and rejection of transplanted immunogenic tumors in p53(-/-) mice. Singh N; Huang L; Qin H Eur J Immunol; 2010 Feb; 40(2):559-68. PubMed ID: 19950180 [TBL] [Abstract][Full Text] [Related]
4. Accumulation of cytolytic CD8+ T cells in B16-melanoma and proliferation of mature T cells in TIS21-knockout mice after T cell receptor stimulation. Ryu MS; Woo MY; Kwon D; Hong AE; Song KY; Park S; Lim IK Exp Cell Res; 2014 Oct; 327(2):209-21. PubMed ID: 25088256 [TBL] [Abstract][Full Text] [Related]
5. Targeting of human p53-overexpressing tumor cells by an HLA A*0201-restricted murine T-cell receptor expressed in Jurkat T cells. Liu X; Peralta EA; Ellenhorn JD; Diamond DJ Cancer Res; 2000 Feb; 60(3):693-701. PubMed ID: 10676655 [TBL] [Abstract][Full Text] [Related]
6. Activation induced cell death (AICD) of human melanoma antigen-specific TCR engineered CD8 T cells involves JNK, Bim and p53. Chhabra A; Mukherji B; Batra D Expert Opin Ther Targets; 2017 Feb; 21(2):117-129. PubMed ID: 27935327 [TBL] [Abstract][Full Text] [Related]
7. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. Prévost-Blondel A; Zimmermann C; Stemmer C; Kulmburg P; Rosenthal FM; Pircher H J Immunol; 1998 Sep; 161(5):2187-94. PubMed ID: 9725210 [TBL] [Abstract][Full Text] [Related]
8. Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice. Hu Z; Xia J; Fan W; Wargo J; Yang YG Oncotarget; 2016 Feb; 7(6):6448-59. PubMed ID: 26824989 [TBL] [Abstract][Full Text] [Related]
9. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy. Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878 [TBL] [Abstract][Full Text] [Related]
10. Coexpression of the T-cell receptor constant alpha domain triggers tumor reactivity of single-chain TCR-transduced human T cells. Voss RH; Thomas S; Pfirschke C; Hauptrock B; Klobuch S; Kuball J; Grabowski M; Engel R; Guillaume P; Romero P; Huber C; Beckhove P; Theobald M Blood; 2010 Jun; 115(25):5154-63. PubMed ID: 20378753 [TBL] [Abstract][Full Text] [Related]
11. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity. Riquelme E; Carreño LJ; González PA; Kalergis AM Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198 [TBL] [Abstract][Full Text] [Related]
12. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy. Hervas-Stubbs S; Mancheño U; Riezu-Boj JI; Larraga A; Ochoa MC; Alignani D; Alfaro C; Morales-Kastresana A; Gonzalez I; Larrea E; Pircher H; Le Bon A; Lopez-Picazo JM; Martín-Algarra S; Prieto J; Melero I J Immunol; 2012 Oct; 189(7):3299-310. PubMed ID: 22925929 [TBL] [Abstract][Full Text] [Related]
13. Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Kuball J; Schmitz FW; Voss RH; Ferreira EA; Engel R; Guillaume P; Strand S; Romero P; Huber C; Sherman LA; Theobald M Immunity; 2005 Jan; 22(1):117-29. PubMed ID: 15664164 [TBL] [Abstract][Full Text] [Related]
14. Local Activation of p53 in the Tumor Microenvironment Overcomes Immune Suppression and Enhances Antitumor Immunity. Guo G; Yu M; Xiao W; Celis E; Cui Y Cancer Res; 2017 May; 77(9):2292-2305. PubMed ID: 28280037 [TBL] [Abstract][Full Text] [Related]
15. Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer. Kobold S; Steffen J; Chaloupka M; Grassmann S; Henkel J; Castoldi R; Zeng Y; Chmielewski M; Schmollinger JC; Schnurr M; Rothenfußer S; Schendel DJ; Abken H; Sustmann C; Niederfellner G; Klein C; Bourquin C; Endres S J Natl Cancer Inst; 2015 Jan; 107(1):364. PubMed ID: 25424197 [TBL] [Abstract][Full Text] [Related]
17. PP6 controls T cell development and homeostasis by negatively regulating distal TCR signaling. Ye J; Shi H; Shen Y; Peng C; Liu Y; Li C; Deng K; Geng J; Xu T; Zhuang Y; Zheng B; Tao W J Immunol; 2015 Feb; 194(4):1654-64. PubMed ID: 25609840 [TBL] [Abstract][Full Text] [Related]
18. Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8(+) T cells. Rubinstein MP; Su EW; Suriano S; Cloud CA; Andrijauskaite K; Kesarwani P; Schwartz KM; Williams KM; Johnson CB; Li M; Scurti GM; Salem ML; Paulos CM; Garrett-Mayer E; Mehrotra S; Cole DJ Cancer Immunol Immunother; 2015 May; 64(5):539-49. PubMed ID: 25676709 [TBL] [Abstract][Full Text] [Related]
19. T-cell receptor gene therapy in human melanoma-bearing immune-deficient mice: human but not mouse T cells recapitulate outcome of clinical studies. Straetemans T; Coccoris M; Berrevoets C; Treffers-Westerlaken E; Scholten CE; Schipper D; Ten Hagen TL; Debets R Hum Gene Ther; 2012 Feb; 23(2):187-201. PubMed ID: 21958294 [TBL] [Abstract][Full Text] [Related]
20. Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating differentiated T cell localization, activation and chemokine production in established breast cancer. Dobrzanski MJ; Reome JB; Hylind JC; Rewers-Felkins KA; Abulsamad K; Adams SL Clin Immunol; 2008 Aug; 128(2):205-18. PubMed ID: 18511346 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]